Findings

What do systematic reviews say?

643 questions · 671 findings · 87 reviews

No studies found 177 · 26.4%GRADE not reported 106 · 15.8%Very low 182 · 27.1%Low 114 · 17%Moderate 66 · 9.8%High 26 · 3.9%

Adverse event: nausea · patients with ALS/MND

The intervention leads to higher adverse event: nausea (high certainty).

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
RR 1.55 [1.06, 2.28]
3 studies · 801 participants
High

Adverse event: asthenia · patients with ALS/MND

The intervention leads to higher adverse event: asthenia (high certainty).

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
RR 1.5 [1.07, 2.12]
3 studies · 801 participants
High

Adverse event: 3‐fold increase in alanine transferase · patients with ALS/MND

The intervention leads to higher adverse event: 3‐fold increase in alanine transferase (high certainty).

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
RR 2.62 [1.59, 4.31]
3 studies · 801 participants
High